PMC7394502_01
Representative images of the rrPMBCL patient during treatment course. (A) PET/CT images before first-line treatment. A FDG-avid bulky mass in the mediastinum, with an enlarged lymph node in the left supraclavicular fossa, is visible. (B) PET/CT images after first-line treatment, no metabolic lesion remained (Deauville score 2). (C) CT images taken 3 months after first-line treatment, lesions (represented by white arrows) reappeared at the primary tumor site. (D) PET/CT images after 2 cycles of salvage chemotherapy, no change in tumor size was observed (Deauville score 5). (E) PET/CT images after radiotherapy with concurrent nivolumab for 3 months, no hypermetabolic lesion is seen (Deauville score 2).
CMAR-12-6311-g0001.jpg
PMC7394502_01_CMAR-12-6311-g0001.jpg
F0001
The SUVmax was as high as 30 (Figure 1A). April 2017. A complete response (CR) was achieved at the end of treatment based on the PET/CT evaluation (Figure 1B) and according to the Lugano classification. Three months after the treatment, recurrence occurred at the primary tumor site indicated by CT scan (Figure 1C). However, the disease remained stable (Figure 1D), with LDH rising to 779 U/L.  A PET/CT-assessed CR was obtained three months after radiation in March 2018 (Figure 1E), when LDH was 181 U/L.
PD-L1 immunohistochemistry. Original magnification 20 x.
CMAR-12-6311-g0002.jpg
PMC7394502_01_CMAR-12-6311-g0002.jpg
F0002
SP263) (Figure 2).